BIS:NSD-ProShares UltraShort Nasdaq Biotechnology (USD)

ETF | Trading--Inverse Equity | NSD

Last Closing Price

USD 22.97

Change

+1.48 (+6.89)%

Market Cap

USD 9.34M

Volume

0.10M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

The investment seeks daily investment results that correspond to two times the inverse (-2x) of the daily performance of the Nasdaq Biotechnology Index®. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.

Company Website : http://www.proshares.com

Currency: USD

Country : USA

Inception Date: 06/04/2010

Primary Benchmark: NASDAQ Biotechnology TR USD

Primary Index: S&P 500 TR USD

Management Expense Ratio: 0.95 %

Technical Indicators

Beta : -1.62

52 Week High : 79.40

Short Ratio : 0.61

52 Week Low : 17.53

Shorted Shares : 5,608

200 Day Moving Average : 26.50

50 Day Moving Average : 19.85

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Symbol Company Name Allocation
AMGN Amgen Inc 8.14 %
GILD Gilead Sciences, Inc 7.41 %
VRTX Vertex Pharmaceuticals Incorporated 7.21 %
BIIB Biogen Inc 6.12 %
ILMN Illumina, Inc 5.67 %
REGN Regeneron Pharmaceuticals, Inc 4.13 %
ALXN Alexion Pharmaceuticals, Inc 3.02 %
SGEN Seagen Inc 2.25 %
INCY Incyte Corporation 2.09 %
BMRN BioMarin Pharmaceutical Inc 1.91 %
Top Sectors

N/A

Top Regions

N/A

Valuation Growth & Performance

Morningstar Ratio : 0

Category Benchmark : S&P 500 TR USD

Sustainability Ratio :

3 Year Volatility : 44.31

3 Year Expected Return : 0.00

3 Year Sharpe Ratio : -0.77

YTD Return : -13.83%

3 Year Returns : -36.19%

5 Year Returns : -35.32%

10 Year Returns : -41.00%

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-03 )

Largest Industry Peers for Trading--Inverse Equity

Symbol Name Mer Price(Change) Market Cap
SQQQ ProShares UltraPro Short QQQ 0.95 %

+1.20 (+8.68%)

 USD1.37B
ZBIO ProShares UltraPro Short Nasda.. 0.95 %

N/A

 USD2.51M

ETFs Containing BIS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Trading--Inverse Equity)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.42% 50% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.42% 50% F 21% F
Trailing 12 Months  
Capital Gain -55.07% 100% A+ 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -55.07% 100% A+ 2% F
Trailing 5 Years  
Capital Gain -86.92% 100% A+ 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -86.92% 100% A+ 3% F
Average Annual (5 Year Horizon)  
Capital Gain -28.22% 100% A+ 4% F
Dividend Return 0.50% 50% F 12% F
Total Return -27.72% 100% A+ 4% F
Risk Return Profile  
Volatility (Standard Deviation) 20.57% 50% F 68% D+
Risk Adjusted Return -134.77% 100% A+ 1% F
Market Capitalization 9.34M 50% F 1% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.